1018 ISS

targets TLR9 via activation

Developed for: Alzheimer disease · cognitive impairment with or without cerebellar ataxia · hepatitis B virus infection · non-Hodgkin lymphoma
Investigated by: Dynavax Technologies Corporation · Access to Advanced Health Institute (AAHI) · Alzheimer's Association · Brigham and Women's Hospital · Dana-Farber Cancer Institute · Fred Hutchinson Cancer Center
+12 more
· HIV Vaccine Trials Network · Hanoi Medical University · Institute of Vaccines and Medical Biologicals, Vietnam · International AIDS Vaccine Initiative · James P. Wilmot Cancer Center · Massachusetts General Hospital · NYU Langone Health · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Hygiene and Epidemiology, Vietnam · United States Department of Defense · University of Rochester · Valneva Austria GmbH

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT06334393	Mar 2024 → Apr 2025	Zika virus infectious disease	Valneva Austria GmbH	Completed	No outcome recorded
Phase 1	NCT05606341	Mar 2023 → Nov 2026 expected	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	NYU Langone Health	Recruiting	No outcome recorded
Phase 1	NCT04830800	Mar → Jun 2021	COVID-19, severe acute respiratory syndrome, viral pneumonia	Institute of Vaccines and Medical Biologicals, Vietnam	Completed	No outcome recorded
Phase 1	NCT04177355	Jan 2020 → Nov 2024	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00426712	Jan 2006 → Mar 2008	hepatitis B virus infection	Dynavax Technologies Corporation	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT05506969	Aug 2022 → Oct 2023	pneumonic plague	Dynavax Technologies Corporation	Completed	No outcome recorded
Phase 2	NCT00251394	Jul 2004 → Dec 2006	non-Hodgkin lymphoma	Dana-Farber Cancer Institute	Completed	No outcome recorded

Also used as a comparator or background therapy in 3 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT06366490 Background	Feb → Nov 2026 expected	ovarian carcinoma	PhotonPharma, Inc.	Recruiting	No outcome recorded
Phase 1	NCT04405908 Comparator	Jun 2020 → Oct 2021	COVID-19	Clover Biopharmaceuticals AUS Pty	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT04764422 Comparator	Mar 2021 → Sep 2022	COVID-19, severe acute respiratory syndrome, viral pneumonia	Mahidol University	Completed	No outcome recorded

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	1018ISS	“the last Rituxan infusion is given, a fourth and final 1018ISS injection will be given.” NCT00251394 ↗ 2 NCT00426712 ↗ NCT00251394 ↗
Known as	Cpg oligonucleotide 1018 iss	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297680 ↗
Known as	CpG1018	“The vaccine series will consist of Innocell cells combined with CpG 1018 adjuvant via intradermal (ID) injection every 2 weeks (14 ± 3 days) x 3 doses.” NCT06366490 ↗ 7 “NDV-HXP-S 1 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM” NCT04764422 ↗ “1 μg +/- CpG1018 (a toll-like receptor 9 agonist)” PMID 35577631 ↗ May 2022 “rF1V vaccine and CpG 1018® adjuvant” NCT05506969 ↗ NCT05606341 ↗ NCT04405908 ↗ NCT06334393 ↗ NCT04177355 ↗
Known as	Iss 1018	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297680 ↗
Known as	Iss 1018 cpg oligodeoxynucleotide	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297680 ↗
Action	Activate	“1 μg +/- CpG1018 (a toll-like receptor 9 agonist)” PMID 35577631 ↗ May 2022
Modality	Oligonucleotide (other)	“immunostimulatory phosphorothiolate oligodeoxyribonucleotide, 1018 ISS” NCT00251394 ↗
Route	Subcutaneous	“Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion.” NCT00251394 ↗
Target	TLR9	“TLR9 agonist” NCT05606341 ↗